PT1531819E - Utilização de inibidores da i capa b cinase na terapia da dor - Google Patents

Utilização de inibidores da i capa b cinase na terapia da dor Download PDF

Info

Publication number
PT1531819E
PT1531819E PT03753349T PT03753349T PT1531819E PT 1531819 E PT1531819 E PT 1531819E PT 03753349 T PT03753349 T PT 03753349T PT 03753349 T PT03753349 T PT 03753349T PT 1531819 E PT1531819 E PT 1531819E
Authority
PT
Portugal
Prior art keywords
kappa
pain
treatment
kinase inhibitors
kinase
Prior art date
Application number
PT03753349T
Other languages
English (en)
Portuguese (pt)
Inventor
Gerhard Jaehne
Karl Rudolphi
Olaf Ritzeler
Gerd Geisslinger
Martin Michaelis
Hans-Georg Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PT1531819E publication Critical patent/PT1531819E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT03753349T 2002-08-17 2003-08-05 Utilização de inibidores da i capa b cinase na terapia da dor PT1531819E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie

Publications (1)

Publication Number Publication Date
PT1531819E true PT1531819E (pt) 2009-02-18

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03753349T PT1531819E (pt) 2002-08-17 2003-08-05 Utilização de inibidores da i capa b cinase na terapia da dor

Country Status (33)

Country Link
EP (1) EP1531819B1 (https=)
JP (1) JP4504811B2 (https=)
KR (2) KR101119845B1 (https=)
CN (1) CN100398107C (https=)
AR (1) AR043045A1 (https=)
AT (1) ATE418336T1 (https=)
AU (1) AU2003271555B2 (https=)
BR (1) BR0313555A (https=)
CA (1) CA2495455C (https=)
CO (1) CO5690585A2 (https=)
CR (1) CR7716A (https=)
CY (1) CY1108874T1 (https=)
DE (2) DE10237723A1 (https=)
DK (1) DK1531819T3 (https=)
EC (1) ECSP055609A (https=)
ES (1) ES2320118T3 (https=)
HR (1) HRP20050041B1 (https=)
IL (1) IL166780A (https=)
MA (1) MA27334A1 (https=)
MX (1) MXPA05001218A (https=)
MY (1) MY138059A (https=)
NO (1) NO334309B1 (https=)
OA (1) OA12907A (https=)
PL (1) PL212356B1 (https=)
PT (1) PT1531819E (https=)
RS (1) RS51878B (https=)
RU (1) RU2320338C2 (https=)
SI (1) SI1531819T1 (https=)
TN (1) TNSN05044A1 (https=)
TW (1) TWI325782B (https=)
UA (1) UA80837C2 (https=)
WO (1) WO2004022057A1 (https=)
ZA (1) ZA200500323B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT2787998T (lt) 2011-12-06 2017-02-10 Sanofi 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-karboksirūgšties [(s)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amido kristalinės formos
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
KR20170021884A (ko) * 2014-07-03 2017-02-28 사노피 골관절염에 연관된 통증의 치료에 사용하기 위한 2-(2-메틸아미노-피리미딘-4-일)-1h-인돌-5-카르복실산 [(s)-1-카르바모일-2-(페닐-피리미딘-2-일-아미노)-에틸]-아미드
CA3106124A1 (en) 2018-07-16 2020-01-23 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1194425T1 (sl) * 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
CN100398107C (zh) 2008-07-02
ECSP055609A (es) 2005-04-18
IL166780A0 (en) 2006-01-15
TWI325782B (en) 2010-06-11
OA12907A (en) 2006-10-13
CA2495455C (en) 2011-01-11
SI1531819T1 (sl) 2009-06-30
RS51878B (sr) 2012-02-29
KR20050058339A (ko) 2005-06-16
IL166780A (en) 2011-11-30
HRP20050041A2 (hr) 2006-04-30
JP2005539053A (ja) 2005-12-22
CR7716A (es) 2008-11-25
TW200417370A (en) 2004-09-16
EP1531819A1 (de) 2005-05-25
MXPA05001218A (es) 2005-05-16
KR101119845B1 (ko) 2012-02-28
WO2004022057A1 (de) 2004-03-18
HRP20050041B1 (hr) 2013-07-31
MY138059A (en) 2009-04-30
HK1079426A1 (en) 2006-04-07
KR20110135428A (ko) 2011-12-16
RU2005107419A (ru) 2005-08-10
DE10237723A1 (de) 2004-07-08
UA80837C2 (uk) 2007-11-12
PL373568A1 (en) 2005-09-05
EP1531819B1 (de) 2008-12-24
MA27334A1 (fr) 2005-05-02
CY1108874T1 (el) 2014-07-02
PL212356B1 (pl) 2012-09-28
BR0313555A (pt) 2005-07-12
CN1674899A (zh) 2005-09-28
DK1531819T3 (da) 2009-04-20
CO5690585A2 (es) 2006-10-31
ES2320118T3 (es) 2009-05-19
RU2320338C2 (ru) 2008-03-27
NO334309B1 (no) 2014-02-03
ATE418336T1 (de) 2009-01-15
RS20050070A (sr) 2007-06-04
NO20051339L (no) 2005-05-03
AR043045A1 (es) 2005-07-13
ZA200500323B (en) 2006-02-22
AU2003271555A1 (en) 2004-03-29
CA2495455A1 (en) 2004-03-18
JP4504811B2 (ja) 2010-07-14
TNSN05044A1 (en) 2007-05-14
AU2003271555B2 (en) 2009-03-26
DE50310980D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
PT1531819E (pt) Utilização de inibidores da i capa b cinase na terapia da dor
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0401605A3 (en) Integrin inhibitors for the treatment of eye diseases
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
GB0213869D0 (en) The treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0211295D0 (en) Treatment of pain
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
GB2410744B (en) Kinase inhibitors for the treatment of disease
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
HUP0402664A3 (en) 2-indanylamino derivatives for the therapy of chronic pain
PL370839A1 (en) Use of proton pump inhibitors for the treatment of airway disorders
PL370840A1 (en) Use of proton pump inhibitors for the treatment of noncardiac chest pain
GB0325957D0 (en) The treatment of pain
GB0216978D0 (en) The treatment of pain
GB0213870D0 (en) The treatment of pain conditions